NCT07477366 2026-03-17
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Not yet recruiting
Clinical Trials
39 trialsNCT06350318 2026-02-05
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07097363 2026-01-15
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Recruiting
NCT04594798 2025-12-17
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
University of Rochester
Phase 2 Active not recruiting
NCT07081022 2025-08-21
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT03505762 2025-08-20
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT03995147 2025-06-08
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
Phase 2 Active not recruiting
NCT06954805 2025-05-02
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Columbia University
Phase 2 Recruiting
NCT04659044 2024-09-19
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Terminated
NCT02564744 2024-06-12
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Debiopharm International SA
Phase 2 Completed
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05929716 2023-11-13
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01238692 2023-03-24
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Jewish General Hospital
Phase 2 Completed
NCT01030900 2022-10-06
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01665768 2021-10-26
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01434472 2021-07-20
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02592876 2019-05-17
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT01980654 2019-04-16
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT00413959 2018-09-19
VRCD
Oncology Specialists, S.C.
Phase 2 Terminated
NCT01925612 2018-06-21
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
Phase 2 Terminated
NCT01812005 2018-06-06
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
NCT00455897 2018-01-18
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT00764517 2017-12-11
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00867087 2017-12-05
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Pfizer
Phase 2 Completed
NCT00895661 2017-06-09
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
Massachusetts General Hospital
Phase 2 Completed
NCT00577629 2017-05-30
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Duke University
Phase 2 Completed
NCT01421667 2016-11-28
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Seagen Inc.
Phase 2 Completed
NCT00588094 2015-12-04
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00169195 2015-09-02
Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma
Lymphoma Study Association
Phase 2 Completed
NCT02456207 2015-05-28
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Sinocelltech Ltd.
Phase 2 Unknown
NCT00081861 2012-04-05
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00216164 2011-05-02
Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00965289 2009-08-26
High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
Nantes University Hospital
Phase 2 Completed
NCT00210379 2009-07-22
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT00927797 2009-06-25
PERLL
Heidelberg University
Phase 2 Unknown
NCT00085696 2008-02-11
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00180895 2006-09-11
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated